Product Description
For Dyslipidemias (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04858308)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Yooyoung Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dyslipidemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04874129 |
YYPCT_YYC506_102 | P1 |
Unknown status |
Dyslipidemia |
2021-05-31 |
2% |
2023-04-04 |
Primary Endpoints|Treatments|Trial Status |
NCT04874142 |
YYPCT_YYC506_P1_DDI | P1 |
Completed |
Dyslipidemia |
2020-03-23 |
2021-05-06 |
Primary Endpoints|Treatments |
|
NCT04858308 |
Atorf-YOOrct | P3 |
Unknown status |
Dyslipidemia |
2021-05-31 |
18% |
2023-04-04 |
Primary Endpoints|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|